Proof-of-concept study holds promise for safer gene therapy techniques for treating immunodeficiencies Post author: Post published:November 1, 2023 Post category:uncategorized Researchers described an approach to edit the recombination-activating gene 2 (RAG2) locus for therapeutic applications. You Might Also Like Ubiquigent partners with Alleo Labs to advance DUB-targeting therapies October 18, 2024 High-performing clinics share effective strategies for chronic care follow-up March 24, 2025 Metrion Biosciences appoints Lee Patterson as CEO November 26, 2024